155 related articles for article (PubMed ID: 38186572)
1. High-throughput computational screening and
Shahrani MA; Gahtani R; Abohassan M; Alshahrani M; Alraey Y; Dera A; Asiri MR; Rajagopalan P
Oncol Res; 2023; 32(2):251-259. PubMed ID: 38186572
[TBL] [Abstract][Full Text] [Related]
2. Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.
Abohassan M; Alshahrani M; Alshahrani MY; Rajagopalan P
Med Oncol; 2022 Oct; 39(12):249. PubMed ID: 36209300
[TBL] [Abstract][Full Text] [Related]
3. Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl
Al Shahrani M; Gahtani RM; Abohassan M; Alasmari S; Makkawi M
Med Oncol; 2023 Oct; 40(11):316. PubMed ID: 37789230
[TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors.
Wang Y; Yin X; Chen L; Yin Z; Zuo Z
Bioorg Chem; 2022 Oct; 127():105868. PubMed ID: 35816874
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR/HER2 dual-target inhibitors.
Jiao X; Zhang Q; Zhang Y; Shao J; Ding L; Tang C; Feng B
Bioorg Med Chem Lett; 2022 Jul; 67():128703. PubMed ID: 35364239
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
[TBL] [Abstract][Full Text] [Related]
8. Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.
Peters XQ; Agoni C; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):505-518. PubMed ID: 35637423
[TBL] [Abstract][Full Text] [Related]
9. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
10. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
[TBL] [Abstract][Full Text] [Related]
11. Computational high-throughput screening and
Tobeigei FH; Gahtani RM; Shaikh A; Al Ali A; Kameli N; Kamli H; Rajagopalan P
Oncol Res; 2021; 29(5):305-318. PubMed ID: 37305163
[TBL] [Abstract][Full Text] [Related]
12. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF
Abou-Zied HA; Beshr EAM; Gomaa HAM; Mostafa YA; Youssif BGM; Hayallah AM; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200464. PubMed ID: 36526595
[TBL] [Abstract][Full Text] [Related]
14. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Sabry MA; Ghaly MA; Maarouf AR; El-Subbagh HI
Eur J Med Chem; 2022 Nov; 241():114661. PubMed ID: 35964425
[TBL] [Abstract][Full Text] [Related]
15. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, in vitro protoporphyrinogen oxidase inhibition, and herbicidal activity of N-(benzothiazol-5-yl)hexahydro-1H-isoindole-1,3-diones and N-(benzothiazol-5-yl)hexahydro-1H-isoindol-1-ones.
Wu QY; Jiang LL; Zuo Y; Wang ZF; Xi Z; Yang GF
Chem Biol Drug Des; 2014 Oct; 84(4):431-42. PubMed ID: 24803371
[TBL] [Abstract][Full Text] [Related]
17. Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines.
Son S; Elkamhawy A; Gul AR; Al-Karmalawy AA; Alnajjar R; Abdeen A; Ibrahim SF; Alshammari SO; Alshammari QA; Choi WJ; Park TJ; Lee K
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2202358. PubMed ID: 37096560
[TBL] [Abstract][Full Text] [Related]
18. Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers.
Ghorab MM; Alsaid MS; Soliman AM
Bioorg Chem; 2018 Oct; 80():611-620. PubMed ID: 30041137
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Potent Dual EGFR/HER2 Inhibitors Based on Thiophene Scaffold Targeting H1299 Lung Cancer Cell Line.
Elrayess R; Abdel Aziz YM; Elgawish MS; Elewa M; Yassen ASA; Elhady SS; Elshihawy HA; Said MM
Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33374155
[TBL] [Abstract][Full Text] [Related]
20. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies.
Hawas SS; El-Sayed SM; Elzahhar PA; Moustafa MA
Bioorg Chem; 2023 Dec; 141():106874. PubMed ID: 37769524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
